Prime Medicine, Inc. Common Stock
PRMEPrime Medicine, Inc. (PRME) is a biotechnology company focused on developing gene editing therapies for genetic diseases. Leveraging its Prime Editing technology, the company aims to create precise, efficient, and versatile treatments to address a range of genetic conditions, with an emphasis on improving patient outcomes through innovative genomic editing solutions.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 12, 2019 | $0.80 | 2019-09-10 | 2019-09-11 |
| June 28, 2019 | $0.20 | 2019-06-14 | 2019-06-17 |
| December 31, 2018 | $0.21 | 2018-12-18 | 2018-12-19 |
| September 28, 2018 | $0.23 | 2018-09-14 | 2018-09-17 |
| June 29, 2018 | $0.15 | 2018-06-21 | 2018-06-22 |
Dividends Summary
- Consistent Payer: Prime Medicine, Inc. Common Stock has rewarded shareholders with 15 dividend payments over the past 4 years.
- Total Returned Value: Investors who held PRME shares during this period received a total of $3.84 per share in dividend income.
- Latest Payout: The most recent dividend of $0.80/share was paid 2501 days ago, on September 12, 2019.
- Yield & Schedule: PRME currently pays dividends quarterly with an annual yield of 46.20%.
- Dividend Growth: Since 2015, the dividend payout has grown by 820.6%, from $0.09 to $0.80.
Company News
The article compares two biotech companies with different risk profiles: Ocular Therapeutix, which has commercial revenue from its Dextenza product and is preparing an FDA application for Axpaxli, versus Prime Medicine, which is developing early-stage Prime Editing gene therapy technology. Despite Prime Medicine's moonshot potential, Ocular Thera...
The regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Bi...
Prime Medicine announced that company management will participate in three upcoming healthcare and biotech conferences in March 2026, including fireside chats at the TD Cowen Health Care Conference and Citizens Life Sciences Conference, as well as 1x1 meetings at the Jefferies Biotech on the Beach Summit. Live webcasts of the fireside chats will ...
The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating signifi...
Prime Medicine published Phase 1/2 clinical data for PM359, an investigational gene therapy for chronic granulomatous disease, demonstrating safety and early clinical efficacy in two patients with promising results in neutrophil restoration and disease symptom improvement.
